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Background: The potential role of decreased respiratory muscle mass, if any, in mediating the
susceptibility to exacerbation in COPD patients has not been determined. We hypothesized
that a decrease in respiratory muscle mass is associated with increased risk of multiple hospital
admissions due to acute exacerbations of the disease.
Methods: Eligible cases and controls (nZ 20) were identified from records of our department’s
pulmonary clinic. Ten subjects diagnosed with COPD (males, 66  7 yr, Body Mass Index
(BMI)Z 26 4 kg/m2) were identified as fragile patients. Fragility was defined as four or more
admissions in the previous year due to severe exacerbations of the disease. Fragile patients
were matched with 10 non-fragile controls, defined as COPD patients who had required only
one admission due to exacerbation of the disease. Criteria for 1:1 matching included ethnicity,
gender, age, BMI, degree of airflow obstruction (i.e., FEV1), comorbidity and chronic treat-
ment. Multiple computed tomography (CT) scan slices were obtained to assess area and atten-
uation coefficients of multiple upper limb, thorax, abdomen and lower limb muscles.
Results: CSA of intercostal and abdominal muscles was significantly decreased in fragile COPD
patients (right side intercostals, mean relative difference (MRD)Z14%, pZ 0.010; OR (95%
CI)Z 2.2 (1.1e4.8), pZ 0.021; left side, MRDZ 13%, pZ 0.007; ORZ 2.2 (1.1e4.5),neumologia, Hospital del Mar, Passeig Marı´tim 25, E-08003 Barcelona, Spain. Fax: þ34 93 221 3237.
delmar.org (M. Orozco-Levi).
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Intercostal muscle mass in multiple exacerbations in COPD 379pZ 0.027). CSA and attenuation coefficients of all other muscle compartments showed no
statistical differences between the two study groups but showed the same trend. Strength
of the inspiratory and expiratory muscles did not differ between the two study groups.
Conclusions: This study shows that the risk for multiple admissions due to a COPD exacerbation
associates with a marked decrease in the CSA of the intercostal muscle compartment.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is
a complex blend of signs and symptoms in patients with
chronic bronchitis and emphysema.1 COPD is a major public
health problem throughout the world because it is a major
cause of morbidity and premature mortality. It jeopardizes
the quality of life of patients and imposes enormous global
healthcare costs.1e3 In Spain, COPD affects about 9% of the
adult population (40e70 years old) and is the fourth cause
of hospital admission and death in this age group.4
COPD has a variable natural history. Some COPD
patients showed a greater risk for frequent and severe
exacerbations. An exacerbation of COPD is defined as an
event in the natural course of the disease characterized by
a change in the patient’s baseline dyspnea, cough and/or
sputum that is beyond normal day-to-day variations, is
acute in onset and may warrant a change in regular medi-
cation in a patient with underlying COPD.1 Exacerbations of
COPD have a high rate of mortality, which worsens with
advancing age.5 Mortality increases with the frequency of
severe exacerbations, particularly if these require admis-
sion to hospital.6 In our setting, it has been shown that the
patients with the greatest mortality risk are those with
three or more acute COPD exacerbations (hazard ratio
4.13).6
Skeletal muscle function (strength and endurance) is
closely related to the absolute quantity of muscle mass,
which is reduced with aging.7e10 This decrease in muscle
mass (sarcopenia) is thought to contribute to the develop-
ment of functional limitations and disability in old age and
to be a potential explanation for part of the association
between muscle strength and mortality.11,12 Respiratory
muscles are essential to alveolar ventilation. The potential
role of decreased respiratory muscle mass, if any, in
mediating the susceptibility to severe exacerbation in COPD
patients has not been determined. In patients with COPD,
these muscles work against increased mechanical loads due
to airflow limitation, geometrical changes in the thorax and
decreased compliance of the chest contents.13 During an
exacerbation there is increased hyperinflation and air
trapping, with reduced expiratory flow and worsening of
VA/Q abnormalities, resulting in severe hypoxemia and
increased mechanical load and dyspnea.1,14,15 We hypoth-
esized that a decrease in respiratory muscle mass is asso-
ciated with an unstable balance between functional muscle
reserve and chronic mechanical and metabolic loadings in
COPD patients prone to acute exacerbations of the disease,
and that this change may be unnoticed by measurements of
muscle strength only. In this study, we sought to determine
whether low respiratory muscle mass, measured with
computed tomography (CT) scanning, would reflect anincreased risk for exacerbation in COPD patients after
adjusting for risk indicators, including age, degree of
airflow obstruction, comorbidities and nutritional status.
Finally, we were able to compare associations on the basis
of isometric inspiratory and expiratory muscle strength.
Condensed methods
Ethics and study design
The cross-sectional study was designed according to the
guidelines for human research16 and approved by the
Research Committee of Human Investigation at the Munic-
ipal Institute for Medical Research (IMIM). The purposes and
characteristics of the study were fully explained to the
patient, without revealing any a priori hypothesis, and
written informed consent was obtained from each
participant.
Sample size
The sample size estimate indicates that 10 patients in the
fragile group compared with 10 non-fragile patients would
permit the detection of 30% of decrease in the cross-
sectional area (CSA) of skeletal muscles, considering a risk
of a< 0.05 and b< 0.20, in bilateral contrast, and esti-
mating a loss of 30%. Calculation of this sample size was
based on the results of a previous study conducted and
published by our group.17
Diagnosis of COPD
Cases and controls were diagnosed with COPD by assess-
ment of both the signs and symptoms of chronic bronchitis
and/or pulmonary emphysema, along with functional
criteria of chronic and irreversible airflow obstruction
(FEV1/FVC< 70%, FEV1< 80% pred) and absence of asthma
as assessed by clinical history and response to bronchodi-
lators (change <12% in FEV1 following 400 mg of inhaled
salbutamol).18e21 Current and former smokers were
included. We followed the guidelines for grading disease
severity in COPD contained in the ATS/ERS guidelines for
staging of COPD.18
Identification of ‘‘fragile’’ COPD patients
For a patient to be enrolled as a case, both a diagnosis of
COPD and absence of comorbidity were required. Fragility
was defined on the basis of the number of admissions (four
or more) in the previous year due to exacerbations of the
disease. Severe exacerbations were predefined as hospital
380 R. Gu¨erri et al.admissions due to acute worsening in PaCO2 associated with
change in the patient’s baseline dyspnea, cough and/or
sputum that was beyond normal day-to-day variations.
Eligible cases were identified from records of the pulmo-
nary outpatient clinic and pulmonary function test labora-
tory of our department. The population of cases consisted
of men older than 50 years, born and living in Spain, who
required multiple admissions in the Department of Respi-
ratory Medicine of the Hospital del Mar (Barcelona, Spain)
due to acute exacerbation of COPD during 2006e2007. At
the time of evaluation, patients with COPD were stable
with no exacerbation of their disease in the preceding two
months and had not experienced recent weight loss.
Patients with COPD receiving regular treatment withTable 1 General and clinical characteristics of the study popul
Non-fragile COPD
Patients, n (%) 10 (50)
Gender, % Males (100)
Age, yrs 63 8
Body mass index, kg/m2
Mean SD 27 5
Range (minemax) 20e34
Cigarette smoking
Never, n (%) 0 (0)
Former, n (%) 7 (60)
Current, n (%) 3 (40)
Pulmonary function
FEV1, %pred 39 10
FEV1, range 16e60
FVC, %pred 57 15
FEV1/FVC, % 51 10
TLC, %pred 107 15
RV, %pred 175 29
TLCO, %pred 60 16
TLCO, range 46e77
PaO2, mmHg 73 13
PaCO2, mmHg 43.1 4.7
Severity of COPD (ATS/ERS)18
Mild, n (%) 0
Moderate, n (%) 0
Severe, n (%) 6 (60)
Very severe, n (%) 4 (40)
Respiratory muscle function
PImax, %pred
Mean SD (range) 64 12 (43e85)
>80, n (%) 3 (30)
60e80, n (%) 1 (10)
<60, n (%) 6 (60)
PEmax, %pred
Mean SD (range) 59 12 (36e76)
>80
60e80, n (%) 6 (60)
<60, n (%) 4 (40)
Admissions in the last year
No, n (%) 10 (100)
Yes, n (%) 0 (0)
Number, mean SD 0
Comorbidity (Charlson Index) 2.3 1.0systemic corticosteroids or under long-term oxygen therapy
were excluded. Patients submitted to invasive mechanical
ventilation or intensive care management were not eligible
for the study.
Identification of ‘‘non-fragile’’ COPD controls
For a subject to be enrolled as a control, a diagnosis of
COPD and absence of comorbidity were required. The
population of controls consisted of men older than 50 years
showing COPD who required their very first admission due
to exacerbation of the disease or any other cause. Although
respiratory muscle thickness does not change significantly
with age,22 age does associate with changes in bothation.
Fragile COPD p Value
10 (50)
Males (100)
69 7 0.218
29 3 0.292
22e32
0 (0) 0.606
8 (70)
2 (30)
36 11 0.579
26e49
55 13 0.912
52 12 0.912
100 9 0.247
146 37 0.105
68 19 0.278
43e70
63 10 0.113
45.5 5.7 0.400
0 0.653
0
5 (50)
5 (50)
62 19 (37e89) 0.579
1 (19)
6 (60)
3 (30) 0.062
72 14 (45e87) 0.052
3 (30)
4 (40)
3 (30) 0.170
0 (0) 0.001
10 (100)
4.7 0.9
2.4 1.4 0.826
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Intercostal muscle mass in multiple exacerbations in COPD 381isometric and dynamic strength23 and is a known risk factor
for COPD.1 On the basis of a 1:1 multivariable matching, we
included ethnicity, gender, age, body mass index (BMI),
degree of airflow obstruction (i.e., FEV1), comorbidity (i.e.,
Charlson index) and chronic treatment as criteria to
establish the closest possible case:control match within
each continuous variable interval. Age intervals were
50e59, 60e69 and 70e79 years. BMI intervals were 20e29.9
and 30e40 kg/m2. FEV1 intervals were according to present
ATS/ERS guidelines for staging of COPD.18 The Charlson
index was included as a method to classify comorbidity.24
Smoking status data
This was collected via a questionnaire. Exhaled CO was
included as a measure to confirm nicotine withdrawal or
continued smoking. Subjects were classified as former
smokers or current smokers.
Nutritional and functional evaluations
Nutritional assessment, pulmonary function tests, and
inspiratory (PImax) and expiratory (PEmax) muscle strength
during maximal maneuvers were measured in each patient
and compared with reference values, as described else-
where25 and in the Supplementary data.
CT and muscle morphometry
CTwas performed at different anatomic levels using a four-
row detector (Somatom Sensation 4, Siemens, Ehrlangen,
Germany) to estimate muscle mass and density of multiple
muscle compartments.26 Computer assisted image software
was used for the analyses. Technical and methodological
specifications appear in the Supplementary data.
Statistical analysis
Subject characteristics are expressed as mean (standard
deviation [SD]) or percentage. Mean values of muscle CT
imaging variables were compared using ManneWhitney U
test. A conditionedmultivariate logistic regressionmodelwas
used to obtain the association between fragility and CSA of
muscle groups after adjusting for potential confounders.27
We tested for interactions between tobacco smoke and
fragility with the logistic model. A p value of less than 0.05
was considered statistically significant. All reported p values
are two-sided. The analysis was performed by two investi-
gators (MOL and JGA), using SPSS for Windows Release 15.0
(2006, SPSS Inc., Chicago, IL, USA). Mouth Pressures (%pred)
Figure 1 Respiratory muscle strength is similar between
fragile and non-fragile COPD patients. Scatter plot for maximal
mouth pressures and pulmonary function variables (FEV1, RV/
TLC ratio and TLC, shown in Fig. 1a, b and c, respectively). A
linear function is lacking between pulmonary function and
maximal inspiratory (PImax, :) or expiratory (PEmax, C) pres-
sures measured at the mouth in this study population. Confi-
dence intervals (95%) are depicted as dotted lines (for PImax)
and continuous lines (for PEmax). Respiratory muscle endurance
was not assessed.Results
Patient characteristics
Table 1 shows the main clinical and functional character-
istics of the 20 subjects (mean age, 66 yr) included in the
present study. All were male smokers with COPD. Demo-
graphic and anthropometric characteristics of the fragile
patients who required multiple hospitalizations werecomparable to the control group. Smoking exposure and
pulmonary function variables were similar between the two
study groups. Strength of the inspiratory and expiratory
muscles did not differ between the two study groups.
Moreover, PImax and PEmax showed no linear function with
the degree of airflow obstruction, air trapping, or total lung
capacity (Fig. 1).
382 R. Gu¨erri et al.CT area and density of multiple muscle
compartments
Using a four-row detector CT (Somatom Sensation 4,
Siemens, Ehrlangen, Germany) a CT at normalized anatomic
levels (Fig. 2) was performed to estimate muscle mass and
density of multiple muscle compartments (Figs. 3 and 4).
Table 3 summarize the mean values of both the size and
attenuation coefficients obtained by measuring upper limb,
lower limb, chest and abdomen muscle compartments in
the two study groups. Costal diaphragm and neck muscles
were not included in the present study assessments. To
perform interindividual comparisons, we calculated indi-
vidual ratios between each muscle area and the femur area
(Table 2). The product of muscle CSA times attenuation
coefficient (i.e., Hounsfield units) was included as an index
of muscle mass. We were able to compare associations on
the basis of isometric inspiratory and expiratory muscle
strength. Statistically significant differences were observed
at intercostal compartments even when adjusted for
potential confounders (age, BMI and FEV1) (Fig. 5). Struc-
tural impairment of the respiratory muscles was greater
than in other muscle compartments. Fig. 4 demonstratesFigure 2 Topographic definition of anatomical levels of acqui
acquisition, we defined the levels of acquisition from a long topog
below the knees (Fig. 2), with the patient in the supine position, h
resting on the side walls of the thighs. From this topogram we defin
dominant arm, obtained at the midpoint between the proximal an
the segment between cranial and caudal ends of the femur, and 3that such a difference is evident even at first glance on CT
images. CSA of intercostal muscles was significantly
decreased in fragile COPD patients (for right side: mean
relative difference (MRD)Z14%, pZ 0.010; OR (95%
CI)Z 2.2 (1.1e4.8), pZ 0.021; for left side: MRDZ13%,
pZ 0.007; ORZ 2.2 (1.1e4.5), pZ 0.027; Table 2, and
Fig. 5). Attenuation coefficients of intercostals were
decreased in fragile COPD (for right side, MRDZ10%,
pZ 0.001; for left side, MRDZ9%, pZ 0.004; Table 2).
Individual values of all study patients are depicted in Fig. 7
to show that size (CSA) of intercostal muscles is comparable
and linearly correlated (r2Z 0.938, p< 0.001) between
right and left body compartments. We attempted to esti-
mate linear correlation between respiratory muscle
strength vs. intercostals and abdominal muscle mass;
however, statistical significance was not reached (Figs. 5
and 6). Difference in abdominal muscles was close to
statistical significance (MRDZ27%, pZ 0.052; Table 2).
The association between intercostal CSA and fragility of
COPD remained statistically significant after adjustments
by age, BMI and smoking. CSA and attenuation coefficients
of all other muscle compartments showed no differences
between the two study groups. Despite the lack ofsition of muscle CT images. To standardize levels of image
ram (1.024 mm), ranging from the lower portion of the neck to
aving legs and feet together and arms next to the body, palms
ed three levels of image acquisition: 1) axial images of the non-
d distal ends of the humerus, 2) leg images, at the midpoint of
) abdomen images, at the level of iliac crest.
Figure 3 Cross-sectional CT images of multiple muscle
compartments. Representative figures showing (a) upper limb,
(b) lower limb, (c) thoracic, (d) paravertebral, and (e)
compartments at normalized anatomical levels. Measures of
both attenuation coefficients (Hounsfield units, HU) and cross-
sectional area (CSA) were obtained using computer assisted
image analysis. For technical specifications, see body of
manuscript.
Figure 4 Cross-sectional area of intercostal muscles is
decreased in fragile COPD as compared with non-fragile COPD
patients. Comparative CT scans showing the difference
between intercostal muscles of a non-fragile patient (4a) and
a fragile COPD (4b).
Intercostal muscle mass in multiple exacerbations in COPD 383statistical significance, changes in the other muscle
compartments showed the same trend (Tables 2 and 3).
Discussion
The present study demonstrates that patients susceptible
to multiple exacerbations (i.e., fragile COPD) show
a decrease in intercostal muscle mass. Both the attenuation
coefficients and area of all other muscle compartments
(upper limb, paravertebrals, psoas and lower limb muscles)
were comparable to patients without prior hospital admis-
sions (i.e., non-fragile COPD). These results reinforce other
findings that COPD associates with not only pulmonary but
also extra-pulmonary alterations28 and that selected
muscle compartments disclose earlier and/or greaterimpairment than others. Furthermore, the results allow the
authors to suggest that specific respiratory muscle wasting
is a predictive variable of susceptibility to and/or the
consequence of severe exacerbations and the likelihood of
hospitalization for COPD patients.
A low BMI has been shown to be an independent indi-
cator of poor prognosis in patients with COPD.29e32 A new
severity classification was proposed: the BODE index (BMI,
airflow obstruction, dyspnea and exercise capacity).33
Nevertheless, it is generally suggested that the true factor
underlying the negative effects attributed to malnutrition
is muscle depletion, not total body weight loss.34,35 The
assessment of nutritional status based on summary
measures such as body weight or BMI has limitations, since
Table 2 Area of upper limb, lower limb and trunk muscle compartments as assessed by CT scan.
(Units) Non-fragile COPD Fragile COPD p Value
Upper limb muscles (non-dominant side)
CSA of middle non-dominant arm (% Femur CSA) 463 91 395 145 0.353
Lower limb muscles
CSA of middle right thigh muscles (% Femur CSA) 1586 193 1557 304 0.905
CSA of middle left thigh muscles (% Femur CSA) 1566 192 1526 284 0.739
Intercostal muscles
CSA of right intercostal muscles (% Femur CSA) 16.7 1.0 14.4 2.1 0.011
CSA of left intercostal muscles (% Femur CSA) 16.6 1.0 14.5 2.1 0.011
Abdominal muscles
CSA of right abdominal wall muscles (% Femur CSA) 572 163 445 240 0.089
CSA of left abdominal wall muscles (% Femur CSA) 570 143 417 223 0.052
Psoas muscles
CSA of right psoas muscle (% Femur CSA) 183 46 183 65 0.684
CSA of left psoas muscle (% Femur CSA) 191 34 182 60 0.280
Paravertebral muscles
CSA of right paravertebral muscle (% Femur CSA) 309 51 295 80 0.646
CSA of left paravertebral muscle (% Femur CSA) 300 48 298 77 0.973
384 R. Gu¨erri et al.it affords no qualitative information on body composition.
Using CT, Heymsfield and Williams36 showed a 20e25%
overestimation in arm muscle area. In an effort to over-
come the limitation of these summary measures, we
selected a multi-slice CT anthropometric assessment for
the present study. X-ray or other anthropometric tech-
niques can detect particular changes in some muscle
compartments even when BMI and body weight are
preserved.26 Bernard et al.37 demonstrated that the
strength of the thigh linearly correlates with muscle CSA
evaluated by CT in COPD patients. Marquis et al.38 showed
that a decrease in the CSA of the thigh (70 cm2) associ-
ated with fourfold increase of mortality risk, independentlyTable 3 Area density product of upper limb, lower limb and
(Unit
Upper limb muscles (non-dominant side)
Area density product of non-dominant middle arm (CSA
Lower limb muscles
Area density product of right thigh muscles (CSA
Area density product of left thigh muscles (CSA
Intercostal muscles
Area density product of right intercostal muscles (CSA
Area density product of left intercostal muscles (CSA
Abdominal muscles
Area density product of right abdominal muscles (CSA
Area density product of left abdominal muscles (CSA
Psoas muscles
Area density product of right psoas muscle (CSA
Area density product of left psoas muscle (CSA
Paravertebral muscles
Area density product of right paravertebral muscle (CSA
Area density product of left paravertebral muscle (CSAof other prognostic variables. Finally, Soler-Cataluna
et al.39 demonstrated that depletion of middle arm muscle
area is an even better predictor of mortality than BMI in
normal weight or overweight patients with COPD.
Our study offers additional evidence supporting the
concept that focal muscle atrophy or wasting associates with
multiple exacerbations. These findings demonstrate that
focal decrease of the mass of selective respiratory muscle
compartments characterizes the group of COPD patients
with greater risk of severe exacerbations. Statistically
significant differences were observed despite the limited
sample size involved. We found that the development of
respiratory muscle wasting is prior and greater to that intrunk muscle compartments as assessed by CT scan.
s) Non-fragile COPD Fragile COPD p Value
 HU) 22,187 3549 18,604 4465 0.064
 HU) 64,057 15,373 52,647 15,267 0.113
 HU) 61,227 14,694 44,541 10,690 0.010
 HU) 728 58 563 56 0.000
 HU) 710 50 570 57 0.000
 HU) 25,872 5433 17,229 7408 0.008
 HU) 26,651 6130 16,145 6619 0.002
 HU) 9007 1531 8088 2264 0.307
 HU) 9501 1235 8723 2268 0.353
 HU) 10,694 2994 10,686 2672 0.995
 HU) 10,473 2613 10,906 2508 0.855
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Figure 5 Cross-sectional area of intercostal muscles is decreased in fragile COPD as compared with non-fragile COPD patients.
Individual and mean measures of all study patients are depicted in the figure. Significant differences were evident in the intercostal
muscle area between fragile (-) and non-fragile (,) COPD patients. Despite this structural difference in the intercostal muscle
compartment, maximal mouth pressures (PImax and PEmax) were not different between the two study groups.
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Figure 6 Cross-sectional area of abdominal muscles in fragile COPD as compared with non-fragile COPD patients. Abdominal
muscles showed a tendency to be depleted in fragile (-) as compared with non-fragile (,) COPD patients but statistical signif-
icance was not achieved.
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Figure 7 Cross-sectional area of right and left intercostal
muscles is correlated. Individual values of all study patients are
depicted to show that size (CSA) of intercostal muscles is
comparable and linearly correlated (r2Z 0.938, p< 0.001)
between right and left thoracic compartments.
386 R. Gu¨erri et al.other trunk or limb muscle compartments. However, the
design of the study does not permit total confidence that the
structural changes within the external intercostals are
representative of inspiratory muscles in general. We
attempted to estimate the correlations between intercostal
and abdominal muscle mass and respiratory muscle strength;
however, the correlation was not satisfactory, probably due
to the participation of other accessory respiratory muscles in
the maneuvers. This lack of difference in muscle strength
suggests that other variables (e.g., muscle endurance)
should be considered as a critical outcome in the study of
clinically stable COPD patients. We support this interpreta-
tion of previous data from a study assessing the lack of linear
relationships between strength and endurance of other
muscles in COPD patients.40 Nevertheless, we speculate that
the absence of differences or correlations between CSA and
muscle strength could also reflect the possibility of inter-
actions between variables and several possibilities incorpo-
rating confounders. In this sense, it is not possible to identify
the specific contribution of intercostals in these maneuvers:
the mass or length of the diaphragm was not assessed;
a potential lengthetension adaptation of the diaphragm
(justified by the sum of individual sarcomere shortening)
could coexist41; CT images did not permit differentiation
between internal (expiratory) and external (inspiratory)
intercostal muscle areas; strength maneuvers (PImax and
PEmax) were performed against an occludable mouthpiece
during isovolume (isometric) contraction of the muscles, but
isokinetic differences cannot be discarded; it is possible that
the magnitude of the lengtheningeshortening CSA can affect
the differences between the two COPD groups; a structural
change from I/ II in the myosin heavy chain isotype could
partially preserve strength at the expense of endurance; and
finally, compliance of the system (lung, chest, abdomen) and
lung volumes are not included in the estimation of normal
predicted values of respiratory muscle strength. Similarly,
Vitacca et al.42 were unable to identify respiratory muscle
function in last stable state as a predictor of functional
worsening (predefined as worsening in PaCO2, PImax and
FEV1) following a period of hospitalization in an intensivecare unit due to exacerbation of COPD. It is remarkable that
blood gases and dynamic and static lung volumes also
showed a lack of predictive capacity in that study.42
Circumstantial evidence supports the relevance of our
study findings. Most variables identified as risk factors for
exacerbation and hospital readmission in COPD patients can
impair respiratory muscle structure and function, directly or
indirectly.43e46 A multi-center study by Garcia-Aymerich
et al.15 in our own study setting found that risk of repeated
exacerbations associates with multiple preventable factors
such as sedentarism, smoking history, lack of prescription for
(or no adherence to) home oxygen therapy, and lack of
respiratory rehabilitation. As shown in Table 1, distribution
of all these variables was comparable between the two study
groups. These patient selection criteria imply that other risk
factors, in addition to gender, age, degree of airflow
obstruction, comorbidity, chronic respiratory failure, chronic
corticosteroid treatment or comorbid conditions, must be
considered a critical cause(s) of selected intercostal muscle
wasting in fragile COPD patients.Potential clinical implications
Respiratory muscle dysfunction in patients with COPD is not
merely a descriptive or anecdotal description. It is associated
with relevant characteristics such as an increase in certain
symptoms (e.g., dyspnea) and signs (hypercapnia, decrease
in exercise capacity).47 Although the descriptive design of
the study does not allow us to establish a causeeeffect
relationship and the pathophysiology of exacerbations in
chronic respiratory diseases appears to bemultifactorial, the
present study’s selection criteria diminish interaction and
biases and make it possible to hypothesize possible physio-
pathological associations. Interestingly, the present report
found that intercostal mass is an additional predictive vari-
able of susceptibility to and/or the consequence of severe
exacerbations in patients with COPD. It seems probable that
different pathogenic mechanisms related to muscle wasting,
and potentially present during exacerbations (e.g., inflam-
mation, oxidative stress, hypoxemia, acidosis), may explain
the present findings.48 We cannot discard, however, an
intrinsic susceptibility to respiratory muscle injury and
wasting in the face of chronic mechanical load imposed by
the disease.25 Identification of these structural changes in
susceptible COPD patients could have important implications
for specific strategies such as respiratory muscle training or
anabolic treatments. Altogether, these arguments suggest
that CSA of the intercostal compartment can be proposed as
an additional (non-redundant) variable offering information
in addition to that obtained only with measurements of
maximal mouth pressures, a fact that is biologically plausible
and offers potential clinical implications. Intercostal wasting
might have occurred prior to, secondary to or in correlation
with exacerbations, and may develop during, afterwards, or
both. Irrespective of the details of this causeeeffect rela-
tionship, intercostal atrophy is statistically associated with
exacerbation rate (risk), a fact that has significant relevance
in the clinical scenario of COPD.
We would not propose CT scan as a screening technique
nor periodical imaging study for the assessment of respira-
tory muscle mass (i.e., CSA) in all patients with COPD. It is
Intercostal muscle mass in multiple exacerbations in COPD 387probable, however, that muscle imaging (CT or others) could
be proposed as complementary assessments in all fragile
patients. Intercostal mass appears as an additional predic-
tive variable of susceptibility to and/or the consequence of
severe exacerbations in patients with COPD. The potential
role of other imaging techniques such as ultrasonography,
which discloses no ionizing radiation risk, should be evalu-
ated before recommending CT scan as the ideal muscle
imaging technique. Identification of these structural changes
in susceptible COPD patients could have important implica-
tions for specific strategies such as respiratory muscle
training or anabolic treatments in a group of patients with
typical fragility and clinical characteristics.
Conclusions
In this report, we show that the risk for multiple admissions
due to exacerbation of COPD associates with a marked
decrease in the CSA of the intercostal muscle compart-
ment, even in the absence of nutritional depletion and
comparable morphology of peripheral muscle compart-
ments. This impairment in intercostal and abdominal
muscles is underestimated when assessing maximal pres-
sures at the mouth. Further studies could identify this
compartmentalized muscle atrophy in fragile COPD patients
as a target for specific strategies such as respiratory muscle
training or anabolic treatments.
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